Endo International plc

305 articles about Endo International plc

• ENDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS

  3/6/2023

  Endo International plc (OTC: ENDPQ) today reported financial results for the fourth-quarter ended December 31, 2022.

• Endo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)

  12/6/2022

  Endo International plc (OTC: ENDPQ) announced today that it will cease the production and sale of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.

• Endo and SMSNA Launch App to Provide Peyronie's Disease Self-Assessment Tool

  10/27/2022

  Endo International plc (OTC: ENDPQ) and the Sexual Medicine Society of North America (SMSNA) announced today the launch of a Peyronie's Self-Assessment application, available now in the App Store and Google Play.

• Endo Presents New Qwo® (collagenase clostridium histolyticum-aaes) Data at the American Society for Dermatologic Surgery's Annual Meeting

  10/7/2022

  Endo International plc (OTC: ENDPQ) announced today that data from studies of Endo Aesthetics' Qwo ® (collagenase clostridium histolyticum-aaes), an FDA-approved injectable for the treatment of moderate to severe cellulite in the buttocks of adult women, will be presented during the American Society for Dermatologic Surgery annual meeting.

• Endo Launches Unscripted Video Series With Real Dupuytren's Contracture Patients

  10/5/2022

  Endo International plc announced the launch of its new branded video series, Coffee & Cords, which aims to educate people about Dupuytren's contracture, a progressive hand condition that results in the formation of a collagen rope-like cord that pulls fingers toward the palm and affects an estimated 14 million Americans.

• 

  Endo Files for Bankruptcy in Wake of Opioid Lawsuits and Mounting Debt - Updated

  8/18/2022

  Endo International filed for bankruptcy Tuesday in the U.S. Bankruptcy Court in New York due to its debt load of over $8 billion and the thousands of opioid lawsuits.

• Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation

  8/17/2022

  Endo International plc announced that it has entered into a restructuring support agreement with holders of more than a majority of Endo's first lien debt on a sale transaction that would substantially reduce outstanding indebtedness, address remaining opioid and other litigation-related claims, and best position Endo for the future.

• ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS

  8/9/2022

  Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2022.

• Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

  7/15/2022

  Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) for the development, registration, supply, commercialization and distribution of QRX003 on an exclusive basis in Canada.

• Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor

  7/1/2022

  Endo International plc (NASDAQ: ENDP) announced today that a federal jury in Chicago, Illinois, has returned a verdict in favor of the Company's subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. (collectively Endo), in an antitrust trial.

• Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder

  7/1/2022

  Endo International plc (NASDAQ: ENDP) today announced top-line results from its Phase 2 study of Collagenase Clostridium Histolyticum (or "CCH") in participants with adhesive capsulitis (AC) of the shoulder, commonly known as "frozen shoulder."

• Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain

  6/13/2022

  Endo International plc announced that its subsidiary Endo Ventures Limited has executed an agreement with Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, to commercialize TLC599, a TLC investigational product.

• TLC Announces TLC599 Agreement with EndoOne of the largest deals seen in Taiwan’s biotech sector

  6/13/2022

  TLC BioSciences announced that it has entered a commercialization agreement with Endo International plc for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain.

• Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting

  5/5/2022

  Endo International plc (NASDAQ: ENDP) today announced the upcoming launch of a new clinical study relevant to the use of Qwo® (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women.

• Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar

  5/2/2022

  Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc.

• Endo to Announce First-Quarter 2022 Financial Results

  4/12/2022

  Endo International plc (NASDAQ: ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, 2022 at 7:30am ET before the U.S. financial markets open.

• Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-to-Use Vials

  3/28/2022

  Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping premixed Ephedrine Sulfate Injection in a ready-to-use 50 mg/10 ml single-use vial.

• Endo Reports Fourth-quarter And Full-Year 2021 Financial Results

  2/28/2022

  Endo International plc reported financial results for the fourth-quarter and full-year ended December 31, 2021 and introduced first-quarter 2022 financial guidance.

• Endo Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles

  2/7/2022

  Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping VASOSTRICT®, vasopressin injection, USP, in ready-to-use 100 mL pre-mix bottles.

• Endo to Announce Fourth Quarter and Full-Year 2021 Financial Results

  1/25/2022

  Endo International plc (NASDAQ: ENDP) will announce its fourth–quarter and full-year 2021 financial results on February 28, 2022 and members of its senior management team will host a conference call and webcast on March 1, 2022 at 7:30am ET before the U.S. financial markets open.